Suda Pharmaceuticals Ltd EPS
¿Qué es el EPS de Suda Pharmaceuticals Ltd?
El EPS de Suda Pharmaceuticals Ltd es -0.02
¿Cuál es la definición de EPS?
Las ganancias por acción (EPS) son la parte de las ganancias de una empresa asignada a cada acción en circulación de acciones ordinarias. Se ajusta para la dilución y se calcula a lo largo de doce meses.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS de compañías en Sector Health Care en ASX en comparadas con Suda Pharmaceuticals Ltd
¿Qué hace Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Empresas con eps similar a Suda Pharmaceuticals Ltd
- Fountainhall Capital Corp tiene EPS de -0.02
- Hong Kong Television Network tiene EPS de -0.02
- China Sandi tiene EPS de -0.02
- BExcellent tiene EPS de -0.02
- Gitennes Exploration Inc tiene EPS de -0.02
- Horizon Gold tiene EPS de -0.02
- Suda Pharmaceuticals Ltd tiene EPS de -0.02
- Collaborate tiene EPS de -0.02
- Kelso Technologies tiene EPS de -0.02
- Shen You tiene EPS de -0.02
- China NT Pharma tiene EPS de -0.02
- Leyou Technologies tiene EPS de -0.02
- Newmac Resources tiene EPS de -0.02